Market Intelligence, Clinical Progress, and High-Purity Reagents for Cell Cycle-Targeted and Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCND3 drug discovery. All products are sequence-verified, >95% purity, endotoxin <1 EU/µg.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & T283A Mutant) | Full-length & Cyclin Box recombinant protein; T283A non-phosphorylatable variant for stability studies | View CCND3 Products |
| Gene Delivery | CCND3 Promise-ORF / Lentivirus for stable cell line construction | View CCND3 Products |
| Benchmark Ab | Anti-CCND3 monoclonal antibody (recombinant positive control) for WB, IHC, flow | View CCND3 Products |
| Validator | CCND3 siRNA set for knockdown and rescue verification | View CCND3 Products |
| Partner Target A | CDK4 Recombinant Protein – direct kinase partner | View CDK4 Products |
| Partner Target B | CDK6 Recombinant Protein – alternative kinase partner | View CDK6 Products |
| Counter Screen | CCND1 (Cyclin D1) Recombinant Protein – paralog for selectivity assays | View CCND1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (CCND1/CCND2 vs CCND3) | Homolog panel strictly verified by mass spec; enables SPR/BLI counter-screens |
| Protein Complex Formation (CCND3-CDK4/6 PPI) | Full-length CCND3 and active CDK4/6 with >95% purity for reliable binding assays |
| Phosphorylation State Dependency (Thr283) | WT/T283A mutant pair available for GSK3β phosphorylation effects |
| Cellular Validation & Degradation | Lentivirus ORF and siRNA set co-validated for rescue experiments and degradation profiling |
| Lack of Controls | Sequence-verified benchmark antibodies and siRNA included as positive/negative controls |
Live CCND3 R&D Tracker
Market data changes daily. Access latest pipeline directly:
Global Clinical Landscape & Future Outlook
While first-generation CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) have revolutionized HR+ breast cancer treatment, clinical resistance driven by cyclin switching (D1 to D3 compensation), CCND3 amplification, and compensatory pathways is now fueling a shift toward direct CCND3 targeting. The next wave of R&D focuses on isoform-specific cyclin D inhibition, targeted protein degradation (PROTACs and molecular glues), and synthetic lethality combinations. Key players include Arvinas, BMS, C4 Therapeutics, Monte Rosa, and Novartis. Indications span hematological malignancies (multiple myeloma, mantle cell lymphoma, DLBCL) and CDK4/6 inhibitor-resistant solid tumors. Future outlook emphasizes overcoming drug resistance, achieving paralog selectivity (CCND3 vs CCND1/CCND2), and developing combination therapies with BCL-2 inhibitors or immunomodulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (CDK4/6 Inhibitor) | Pfizer, Novartis, Eli Lilly | HR+ Breast Cancer, MCL | Enzymatic assay with complex formation |
| Targeted PPI Inhibitor | Emerging Biotech / Academic Consortia | Mantle Cell Lymphoma, Myeloma | SPR/BLI binding assay using high-purity CCND3-CDK4/6 |
| PROTAC / Molecular Glue | Arvinas, BMS, C4 Therapeutics, Monte Rosa | Refractory Myeloma, Lymphoma, CDK4/6i-resistant solid tumors | Ternary complex formation (CCND3 + CDK4/6 + E3 ligase) |
| Bi-specific Degrader | Arvinas, Monte Rosa | Refractory Multiple Myeloma | Cellular degradation assay (need lentivirus stable lines) |
| RNAi / Antisense | Alnylam, Ionis | Advanced Solid Tumors | Knockdown validation (need validated siRNA) |
Key Functional Domains and Known Mutations
- Cyclin N-terminal domain (UniProt P30281): Essential for CDK4/6 binding and cell cycle progression from G1 to S phase.
- Key polymorphisms from dbSNP: rs3218089, rs33966734, rs1051130 – variants associated with altered CCND3 stability or cancer risk.
- T283A mutation: Non-phosphorylatable at GSK3β site; widely used to study phosphorylation-dependent degradation.
Assay Strategy and Molecular Differentiation
Affinity, Selectivity, and Mechanism
- Primary screening: AlphaLISA/TR-FRET with biotinylated CCND3 and His-CDK4/6.
- Paralog selectivity: Parallel IC50 measurement on CCND1/CCND2/CCND3 panel (TarMart provides all three).
- Ternary complex validation: SPR using CCND3, CDK4/6, and E3 ligase (CRBN/VHL) for degraders.
Cellular and Mechanistic Validation
- Degradation kinetics: Use CCND3 Lentivirus overexpressing cell lines with Western blot or HiBiT monitoring.
- Target engagement: Cellular thermal shift assay (CETSA) with anti-CCND3 benchmark antibody.
- Rescue experiments: siRNA knockdown followed by ORF reintroduction confirms specificity.
TarMart Advantage
- All recombinant proteins (CCND3 WT, T283A mutant, CCND1, CDK4, CDK6) >95% pure, sequence verified, low endotoxin.
- Lentivirus and siRNA sets optimized for rapid cell line construction and knockdown validation.
- Benchmark antibody suitable for IHC, WB, and flow cytometry as standard controls.
For detailed product inquiries, visit View CCND3 Products.